Wyeth Reports Earnings Results for the 2007 Third Quarter and First N...(ine months together with thepercentage c...),Health

(UNAUDITED)

Three Months Ended Nine Months Ended

9/30/2007 9/30/2007

Increase/

Principal Products ($ in millions)(Decrease) ($ in millions) Increase

Effexor $958 4% $2,826 1%

Prevnar 634 24% 1,883 29%

Enbrel (outside the

U.S. and Canada) 527 39% 1,480 37%

Protonix 425 (6)% 1,450 5%

Nutrition 346 13% 1,050 17%

Alliance Revenue (1) 314 (12)% 973 -

Zosyn/Tazocin 284 16% 845 17%

Premarin Family 283 8% 791 -

Centrum 174 1% 501 5%

Advil 178 18% 498 11%

(1) Alliance revenue reflects revenue to Wyeth derived from sales of Enbrel (in the United States and Canada), Altace and the CYPHER stent.

Enbrel(R) continued to post strong revenue growth during the 2007 third quarter. Wyeth has exclusive rights to Enbrel outside of the United States and Canada. Enbrel sales in the United States and Canada are expected to be reported by Wyeth's marketing partner Amgen Inc. on Wednesday, October 24, 2007.

Enbrel is a breakthrough product approved for the treatment of chronic inflammatory diseases, including rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis. Enbrel is now ranked sixth among the top pharmaceutical products ranked globally by sales and is
'/>"/>